Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Hormonal & Endocrine•Updated 2026-02-01•5 min read

    What Is PTH 1-34? Benefits, Research & Safety

    The biologically active fragment of parathyroid hormone approved for osteoporosis treatment, representing the first anabolic bone therapy.

    Share:X PostLinkedIn
    Also known as:
    Teriparatide
    Forteo
    Parathyroid Hormone Fragment
    AStrong human evidenceUK: Prescription-only (UK POM)WADA: Low sport risk

    UK summary: UK prescription-only medicine (Forsteo / teriparatide). First-line anabolic osteoporosis therapy for severe disease or where anti-resorptive therapy has failed. Time-limited course (typically 2 years).

    Quick Facts

    Category
    Hormonal & Endocrine
    Half-Life
    Approximately 1 hour when given subcutaneously
    UK Status
    Approved (Forsteo) for severe osteoporosis.
    EU Status
    Approved for osteoporosis when other treatments unsuitable or failed.

    Overview

    PTH 1-34, known therapeutically as teriparatide (Forteo/Forsteo), is a recombinant form of the first 34 amino acids of human parathyroid hormone. This fragment contains the biologically active portion of the full 84-amino acid PTH molecule and is sufficient for full receptor activation. While parathyroid hormone is often associated with bone loss (as in hyperparathyroidism), intermittent administration of PTH 1-34 has the opposite effect—it stimulates new bone formation. This paradox was a key insight that led to development of anabolic osteoporosis therapy. Teriparatide was the first approved anabolic agent for osteoporosis, offering an alternative to anti-resorptive treatments (bisphosphonates, denosumab) that only slow bone loss. It is particularly valuable for severe osteoporosis and patients who have failed or cannot tolerate other treatments. The medication works by stimulating osteoblasts (bone-building cells) to form new bone, increasing bone density and improving bone architecture. This leads to significant reductions in both vertebral and non-vertebral fractures. Treatment is limited to 2 years due to theoretical concerns about osteosarcoma seen in rat studies (not observed in humans). Following teriparatide treatment, patients typically transition to anti-resorptive therapy to maintain gains.
    Evidence standards summary

    PTH 1-34 — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    AStrong human evidenceOverall grade against our evidence grading methodology.

    UK prescription-only medicine (Forsteo / teriparatide). First-line anabolic osteoporosis therapy for severe disease or where anti-resorptive therapy has failed. Time-limited course (typically 2 years).

    02Human evidence grade

    AStrong human evidenceStrength of evidence from published human trials.

    03Preclinical evidence grade

    AStrong human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Approved (Forsteo) for severe osteoporosis.
    • EU: Approved for osteoporosis when other treatments unsuitable or failed.
    • Notes: Teriparatide is approved in UK, EU, US, and many other countries. Usage criteria vary; often reserved for severe cases or treatment failures. Biosimilars are now available in some markets.

    05Approved medical uses

    • Severe postmenopausal osteoporosis (Forsteo — MHRA-licensed POM, NICE TA161, max 24 months).
    • Osteoporosis in men at high fracture risk.
    • Glucocorticoid-induced osteoporosis.

    06Unapproved / promotional claims

    • General bone-density supplement.
    • Sports performance through bone strengthening.
    • Replaces bisphosphonates as first-line.

    07Common internet claims

    • Marketed by some online sources as bodybuilding bone-density boost.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Builds bone faster than bisphosphonates”AYesLowTeriparatide is anabolic (forms new bone); bisphosphonates are anti-resorptive (slow bone loss). They work differently; teriparatide is generally reserved for severe disease.

    09Safety uncertainty score

    Moderate

    Safety profile partly characterised; some signals from observational or preclinical data.

    10Known adverse signals

    • Transient hypercalcaemia, leg cramps, nausea, orthostatic hypotension.
    • Osteosarcoma rodent signal (limits use to 24 months).
    • Contraindicated in Paget's, prior radiation, hypercalcaemia, hyperparathyroidism.

    11Drug-interaction uncertainty

    Moderate

    Some interaction data published; check with a prescriber for your specific medicines.

    12Anti-doping status

    WADA: Low sport riskWADA strict-liability framing applies.

    13UK legal position

    UK: Prescription-only (UK POM)

    Approved (Forsteo) for severe osteoporosis.

    14EU legal position

    Approved for osteoporosis when other treatments unsuitable or failed.

    15What this page cannot tell you

    • Whether grey-market 'PTH 1-34' products contain the labelled compound at safe concentration.
    • Long-term safety beyond 24 months in any patient population.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • Comparative-effectiveness vs romosozumab in head-to-head Phase 3 settings.

    19Safer alternatives / established care pathways

    • NICE TA161 osteoporosis pathway under endocrinology / rheumatology.
    • Bisphosphonate first-line per NICE.

    Related Safety Centre page → Prescription-only medicines

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Am I eligible for teriparatide given my osteoporosis severity?

    Discovery & History

    Parathyroid hormone was identified in the early 20th century as the factor controlling calcium homeostasis. For decades, it was primarily associated with hypercalcemia and bone loss in hyperparathyroidism. The surprising observation that intermittent PTH administration could increase bone mass dates to the 1970s and 1980s. Researchers found that while continuous PTH caused bone resorption, pulsed/intermittent exposure stimulated bone formation—a phenomenon sometimes called the "anabolic window." Studies in osteoporotic patients in the 1990s demonstrated that daily PTH injections increased bone density and reduced fractures. The 1-34 fragment was found to have full biological activity and was easier to produce recombinantly. The pivotal Fracture Prevention Trial demonstrated significant reductions in vertebral and non-vertebral fractures with teriparatide. The FDA approved teriparatide (Forteo) in 2002 for postmenopausal osteoporosis. The rat osteosarcoma signal observed in preclinical studies led to a boxed warning and the 2-year treatment limitation, though no increase in osteosarcoma has been observed in humans even with long-term surveillance. Subsequent developments include abaloparatide (PTHrP analogue) and combination/sequential therapy studies optimising the anabolic-to-antiresorptive transition.

    Mechanism of Action

    PTH 1-34 exerts its bone-forming effects through the PTH1 receptor: **PTH1R Activation** PTH 1-34 binds to the PTH1 receptor on bone cells: - G protein-coupled receptor - Activates cAMP and calcium signaling - Effects depend on exposure pattern (intermittent vs continuous) **Osteoblast Stimulation (Anabolic Effect)** Intermittent exposure promotes bone formation: - Increases osteoblast number and activity - Enhances osteoblast survival (anti-apoptotic) - Stimulates synthesis of bone matrix proteins - Promotes differentiation of osteoblast precursors **Bone Remodeling Shift** Changes the balance toward formation: - Increases bone formation rate - Improves trabecular architecture - Increases cortical thickness - Net gain in bone mass and strength **The Anabolic Window** Why intermittent beats continuous: - Brief PTH exposure favors formation - Prolonged exposure leads to resorption - Daily injection creates "anabolic window" - Withdrawal before catabolic phase sets in **Effects on Bone Geometry** Beyond density: - Improves trabecular connectivity - Increases cortical porosity initially (later resolves) - May improve bone quality independent of density

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Significant reduction in vertebral fractures (65-70%)
    • 2
      Reduction in non-vertebral fractures (35-50%)
    • 3
      Substantial increases in bone mineral density
    • 4
      Improved bone architecture and quality
    • 5
      Effective in severe osteoporosis and prior fractures
    • 6
      Can be used when anti-resorptives have failed

    Claim vs Evidence

    How popular claims about PTH 1-34 stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Builds bone faster than bisphosphonates”AYesLowTeriparatide is anabolic (forms new bone); bisphosphonates are anti-resorptive (slow bone loss). They work differently; teriparatide is generally reserved for severe disease.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical Dosage20 mcg subcutaneous injection daily
    FrequencyOnce daily
    DurationUp to 24 months (2 years maximum per current labeling)
    NotesTeriparatide is a prescription medication for severe osteoporosis. Treatment duration is limited. Should be followed by anti-resorptive therapy to maintain bone gains. Medical supervision and monitoring required.

    Administration Routes

    Routes studied in research settings (educational only):

    • Subcutaneous injection (daily)
    • Pen device for self-administration
    Half-LifeStability
    Approximately 1 hour when given subcutaneouslyRequires refrigeration; stable per manufacturer specifications

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Nausea
    • Headache
    • Dizziness
    • Leg cramps
    • Injection site reactions
    • Transient hypercalcemia

    Rare Risks & Concerns

    • Osteosarcoma (boxed warning based on rat studies; not observed in humans)
    • Hypercalcemia requiring dose adjustment
    • Orthostatic hypotension (early doses)

    Contraindications

    • Prior radiation to skeleton
    • Bone metastases or history of skeletal malignancy
    • Metabolic bone diseases other than osteoporosis
    • Pre-existing hypercalcemia
    • Pediatric populations with open epiphyses
    • Paget's disease

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Approved (Forsteo) for severe osteoporosis.

    🇪🇺 European Union

    Approved for osteoporosis when other treatments unsuitable or failed.

    Teriparatide is approved in UK, EU, US, and many other countries. Usage criteria vary; often reserved for severe cases or treatment failures. Biosimilars are now available in some markets.

    Clinical Studies Summary

    Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

    Pivotal trial demonstrating significant reduction in vertebral and non-vertebral fractures with teriparatide.

    N Engl J Med. 2001View on PubMed

    Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.

    Limitations of the study included considerable population overlap between the reports, incomplete data, and heterogeneity in the protocol design.

    J Bone Miner Res. 2022View on PubMed

    Potential effects of teriparatide (PTH (1-34)) on osteoarthritis: a systematic review.

    The SR demonstrated that PTH (1-34) could alleviate the progression of OA. Moreover, PTH (1-34) had beneficial effects on osteoporotic OA (OPOA) models, which might be a therapeutic option for OA and OPOA treatment.

    Arthritis Res Ther. 2023View on PubMed

    Impact of recombinant PTH on management of hypoparathyroidism: a systematic review.

    Of 2,141 studies identified, only eleven studies fitted the inclusion criteria. These studies suggest that rPTH is useful in normalising serum calcium levels. Excretion of urinary calcium levels is reduced with PTH 1-34 but remained unchanged in a number of studies using PTH 1-84. Recombinant PTH is well tolerated. The majority of studies included post-surgical hypoparathyroidism with marked heterogeneity.

    Eur Arch Otorhinolaryngol. 2016View on PubMed

    Parathyroid hormone and its related peptides in bone metabolism.

    The action mechanism of these PTH-related peptides is not exactly the same as that of PTH. Thus, the mechanisms of PTH and PTH-related peptides in bone metabolism were reviewed in this paper.

    Biochem Pharmacol. 2021View on PubMed

    Abaloparatide and the Spine: A Narrative Review.

    Abaloparatide (synthetic parathyroid-related peptide (PTHrP), Tymlos, Radius Health, Waltham, MA), the second drug in this family, has recently become available for use. In this narrative review, we review the mechanism, effects, and benefits of abaloparatide compared to alternative treatments as well as discuss the current literature in regard to its effect on osteoporosis-related complications in the spine.

    Clin Interv Aging. 2020View on PubMed

    Registered Trials & Regulatory Status

    Registered trials
    102
    Currently recruiting
    1
    Furthest phase
    Phase 4
    Approved product
    No

    32 of 66 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

    To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

    PHASE3

    Status: Not Yet Recruiting · 282 participants · Qilu Pharmaceutical Co., Ltd.

    Conditions: Postmenopausal Women With Osteoporosis

    No results postedNCT06898060

    Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCT

    PHASE1/PHASE2

    Status: Not Yet Recruiting · 80 participants · University of Calgary

    Conditions: Ankle Fractures

    No results postedNCT06303284

    Precision Medicine Approach for Osteoporosis - Follow Up Study

    PHASE4

    Status: Enrolling By Invitation · 40 participants · Paul F Netzel

    Conditions: Osteoporosis

    No results postedNCT06264609

    Teriparatide on Maxillary Sinus Floor Osseointegration

    PHASE4

    Status: Unknown · 42 participants · Universidad de Valparaiso

    Conditions: Bone Regeneration

    No results postedNCT06061354

    Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

    PHASE1

    Status: Completed · 45 participants · Entera Bio Ltd.

    Conditions: Hypoparathyroidism, Osteoporosis, Fractures, Bone

    No results postedNCT05965167

    Fracture Recovery for Returning to Duty (Teriparatide STRONG)

    PHASE4

    Status: Enrolling By Invitation · 183 participants · University of South Carolina

    Conditions: Stress Fracture of Tibia or Fibula

    No results postedNCT04589819

    Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

    PHASE4

    Status: Active Not Recruiting · 60 participants · Madhumathi Rao

    Conditions: Age-Related Osteoporosis

    No results postedNCT05151484

    Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

    PHASE1

    Status: Completed · 50 participants · RANI Therapeutics

    Conditions: Healthy Volunteers

    No results postedNCT05164614

    Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease

    PHASE4

    Status: Recruiting · 48 participants · Ditte Hansen

    Conditions: Adynamic Bone Disease, Chronic Kidney Diseases, Cardiac Disease

    No results postedNCT04522622

    Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

    N/A

    Status: Completed · 22,054 participants · Radius Health, Inc.

    Conditions: Osteoporosis, Postmenopausal

    Results postedNCT04974723

    Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between Sexes

    PHASE3

    Status: Completed · 30 participants · Norfolk and Norwich University Hospitals NHS Foundation Trust

    Conditions: Stress Fracture

    No results postedNCT04921124

    Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin on the Bone Metabolism and Aging

    NA

    Status: Terminated · 99 participants · University of Milano Bicocca

    Conditions: Bone Metabolism Disorder, Aging Disorder, Osteoporosis

    No results postedNCT04669782

    Adverse event reports (FDA FAERS)

    Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

    Source: ClinicalTrials.gov and openFDA. Updated automatically.

    Looking for PTH 1-34?

    Source research-grade PTH 1-34 from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about PTH 1-34

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Am I eligible for teriparatide given my osteoporosis severity?

    UK regulatory & safety context

    Prescription-only medicines

    Safety Centre guide

    Related Peptides

    ACTH

    A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.

    Learn more

    Amylin

    A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.

    Learn more

    Calcitonin

    A thyroid hormone involved in calcium regulation, used therapeutically for osteoporosis, Paget's disease, and hypercalcemia.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.